Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)

PHASE4CompletedINTERVENTIONAL
Enrollment

4,570

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

May 31, 2008

Conditions
Coronary DiseaseAngina Pectoris
Interventions
DRUG

Bivalirudin

bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.

DRUG

Un-fractionated heparin

UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.

Trial Locations (4)

23795

Segeberger Kliniken, Bad Segeberg

79189

Herz-Zentrum, Bad Krozingen

80636

Deutsches Herzzentrum Muenchen, Munich

81675

First Medizinische Klinik, Klinikum rechts der Isar, Munich

All Listed Sponsors
lead

Deutsches Herzzentrum Muenchen

OTHER

NCT00262054 - Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) | Biotech Hunter | Biotech Hunter